Harrow (HROW) is back in focus after the company re-launched VERKAZIA, a cyclosporine ophthalmic emulsion for vernal keratoconjunctivitis, supported by a broad push around physician education, patient access, and affordability.

Harrow’s recent VERKAZIA news has coincided with a sharp shift in sentiment, with the share price up 29.91% over 30 days and 26.09% over 90 days, yet still showing a year-to-date share price decline of 14.11%. At the same time, longer term total shareholder returns of 39.82% over one year and more than 3x over five years point to momentum that has built over time rather than faded.

If you are looking beyond Harrow for other eyecare and broader healthcare opportunities, it can be useful to see what is happening in specialised healthcare technology, including 40 healthcare AI stocks

With Harrow’s share price climbing in recent weeks and analysts’ targets sitting well above the last close, the key question is whether the current valuation still leaves room for upside or if the market is already pricing in future growth.

Most Popular Narrative: 37.3% Undervalued

Compared with Harrow’s last close at $42.87, the most widely followed narrative points to a fair value of $68.38. This creates a sizeable valuation gap for investors to assess.

The rapidly growing demand for Harrow's portfolio of specialty ophthalmic drugs, particularly VEVYE, IHEEZO, and TRIESENCE, is positioned to accelerate further as aging populations and increased prevalence of chronic ocular diseases expand the baseline patient pool supporting sustainable long-term revenue growth.

Curious what sits behind that gap between Harrow’s current price and the narrative fair value? The story leans heavily on fast revenue expansion, rising margins and a future earnings multiple that assumes the market treats Harrow more like a scaled, mature eyecare platform rather than a niche player.

Result: Fair Value of $68.38 (UNDERVALUED)

However, Harrow’s heavy reliance on a handful of flagship products, along with its sensitivity to drug pricing and reimbursement, could quickly challenge this undervaluation narrative if expectations reset.

Next Steps

With sentiment around Harrow clearly split, it helps to move quickly, review the underlying data and come to your own conclusion while the story is still evolving. To see what optimists are focusing on, take a closer look at the 2 key rewards

Looking for more investment ideas beyond Harrow?

Do not stop your research with Harrow. Broaden your watchlist with fresh opportunities that match your risk, income, and quality preferences using the Simply Wall Street Screener.

• Target potential mispricings by scanning companies that combine quality fundamentals with attractive valuations through the 45 high quality undervalued stocks.
• Build a portfolio focused on income by uncovering higher yielding opportunities using the 8 dividend fortresses.
• Prioritise resilience by filtering for companies that score well on financial strength and stability via the 66 resilient stocks with low risk scores.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.